

1645
#2
6/13/02
82

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A0000428-01-CFP

In Re Application Of: **WILLIAM GLEN HARTER, ET AL**

O I P E J C 1
JUN 10 2002
PATENT & TRADEMARK OFFICE
Serial No.
10/075,073

Filing Date
February 13, 2002

Examiner
Unknown

Group Art Unit
1645

Title: **FUSED PYRIMIDINONE MATRIX METALLOPROTEINASE INHIBITORS**

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
 - the statement specified in 37 CFR 1.97(e);

OR
 - the fee set forth in 37 CFR 1.17(p).


RECEIVED
JUN 12 2002
TECH CENTER 1600/280

No References Recvd.

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A0000428-01-CFP

In Re Application: WILLIAM GLEN HARTER, ET AL.



JUN 10 2002

Serial No.

10/075,073

Filing Date

February 13, 2002

Unknown

Group Art Unit

1645

FUSED PYRIMIDINONE MATRIX METALLOPROTEINASE INHIBITORS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0455 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited May 31, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Nancy D Dernbach

Signature of Person Mailing Correspondence

Nancy Dernbach

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Claude F. Purchase, Jr.
Signature

Dated: May 31, 2002

Claude F. Purchase, Jr.

Registration No. 47,871

Warner-Lambert Company

Patent Department

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553


CC:

RECEIVED
JUN 12 2002
TECH CENTER 1600/2000

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 6 Attorney Docket Number A0000428-01-CF

Complete if Known

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1615 1624
Examiner Name	Unknown

井2

RECEIVED
JULY 12 2002
TECH CENTER 1600280

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Office ³	Number ⁴				
	WO	01/63244	A1	Chen, et al	08/30/2001		
	WO	97/07119		Furuya, et al	02/27/1997		
	WO	98/54116		Castelhano, et al	12/03/1998		
	WO	96/22991		Meyer, et al	08/01/1996		
	WO	95/28405		Furuya, et al	10/26/1995		
	WO	92/20687		Chakravarty, et al	11/26/1992		
	WO	00/61583		Klein, et al	10/19/2000		
	WO	00/04027		Meyer, et al	01/27/2000		
	WO	98/49899		Atherall, et al	11/12/1998		
	EP	0 530 537	B1	Akimoto, et al	01/08/1997		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 2 of 6

Sheet 2 of 6 Attorney Docket Number

Cmpl t if Known

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴				
		EP	0 443 568 A1	Morimoto, et al	08/28/1991		
		EP	0 443 568 B1	Morimoto, et al	06/12/1996		
		EP	0 492 316 A1	Akimoto, et al	07/01/1992		
		EP	0 502 725 A2	de Laszlo	09/09/1992		
		EP	0 530 537 A1	Akimoto, et al	03/10/1993		
		EP	0 416 740 A2	Smith, et al	03/13/1991		
		EP	0 297 661 B1	Janssens, et al	09/16/1992		
		EP	0 438 261 A2	Akimoto, et al	07/24/1991		
		EP	0 297 661 A1	Janssens, et al	01/04/1989		
		EP	0 282 133 B1	Janssens, et al	07/28/1993		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of

Digitized by srujanika@gmail.com

Sheet 3 of 6

Complete if Known --

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645 / 1624
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

Sheet 3 of

Attorney Docket Number A0000428-01-CFP

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

卷之三

FOREIGN PATENT DOCUMENTS

6

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

6

C mpt te if Known

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645 1624
Examiner Name	Unknown

Attorney Docket Number A0000428-01-CFP

RECEIVED
JUN 1 2 2002
TECH CENTER 1600/2000

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25
		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654
		HIROTA, Kosaku, et al, "Synthesis of 6-Substituted Thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones", J. Heterocycl. Chem., 1990; 27(3); pp 717-721
		RAJAPPA, S., et al, "Synthesis of Thiophenes: Part III* - Further Variations in the Substitution Pattern", Indian J. Chem., Vol. 12, 1974; pp 1-3
		HCAPLUS Abstract 1998: 542760; "Preparation of bicyclic-substituted hexahydrobenz [e] isoindoles as a1 adrenergic antagonists"
		HCAPLUS Abstract 1990: 514925; "Pyrimidines. 65. Synthesis of 6-substituted thieno [2,3-d] pyrimidine-2 4(1H,3H) - diones"
		HCAPLUS Abstract 1974: 463420: "Synthesis of thiophenes. III. Further variations in the substitution pattern"
		Derwent Abstract 2000-687031/67, "New xanthine derivatives are inhibitors of cellular processes mediated by interleukin-12 for treating inflammatory responses e.g. chronic inflammatory disease, chronic intestinal inflammation, arthritis, psoriasis and asthma (Eng)"
		Derwent Abstract 92-415690/50, "New Pyrimidinone derivs. are angiotensin II antagonists - for treating hypertension, congestive heart failure, renal failure, Alzheimer's disease, amnesia schizophrenia etc (Eng)"
		Derwent Abstract 92-302020/37, "New fused pyrimidone derivs. - are angiotensin II antagonists to treat hypertension, congestive heart failure, Alzheimer's disease, amnesia, anxiety, schizophrenia, etc. (Eng)"

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6 Attorney Docket Number A0000428-01-CFP

Compl t if Known

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645
Examiner Name	Unknown

TECH CENTER 1600/2000

RECEIVED
JUN 12 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Derwent Abstract 91-254180/35, "New angiotensin-II antagonising fused thiophene derivatives - used for treating hypertension and circulatory diseases including heart diseases and stroke"
		Derwent Abstract 89-192246/26, "New 3-piperidinyl:alkyl-thieno: or furo pyrimidine-2,4-di:one cpds. - useful as serotonin antagonists and alpha adrenergic blockers"
		Derwent Abstract 2000-195023/17, "New ipiperazinyl pyrimidine dione derivatives used as selective alpha-1D adrenoceptor antagonists for treating benign prostatic hyperplasia, hypertension, detrusor instability and incontinence (Eng)"
		Derwent Abstract 2001-158207/16, "New piperazinyl pyrimidine dione derivatives are selective alpha-1D adrenoceptor antagonists used for treatment of e.g. hypertension"
		Derwent Abstract 96-362624/36, "New bi:cyclic subst. hexa:hydro-benz-isoindole derivs. - are alpha-1 adrenergic antagonists, used in treatment of benign prostatic hyperplasia (Eng)"
		Derwent Abstract 89-008928/02, "New bi:cyclic heterocycle subst. hexa-hydro-1H-azepine - and pyrrolidine cpds., have anti-histaminic properties, for treatment of e.g. allergic rhinitis, allergic asthma, etc."
		Derwent Abstract 88-258874/37, "New 1-alkyl subst. benzimidazole derivs. - having anti-histaminic activity and used for treating allergic diseases such as allergic asthma"
		Derwent Abstract 91-216939/30, "New condensed heterocyclic glutemic acid derivs., - active against enzyme using folic acid and antitumour agents for treating e.g. leukemia"
		Derwent Abstract 99-080786/07, "New thiophene- and pyrrole-based hetero-aromatic compounds - are (ant)agonists of cell surface receptors, useful e.g. for inhibiting unwanted cell growth e.g. due to cancer (Eng.)"
		Derwent Abstract 97-165234/15, "New thieno-pyrimidine derivs. are endothelin antagonists - useful for treating e.g. acute renal failure, cardiac infarction, liver insufficiency, organ hypo-function and vasoconstriction (Eng)"
		Derwent Abstract 96-384384/38, "New 2,4(1H, 3H)-di:oxo-5-(aminoalkyl)thieno(2,3-d)-pyrimidine derivs. - are gonadotropin-releasing hormone antagonistic agents useful in prevention and treatment of sex hormone dependent diseases (Eng)"

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

6

- Cmplt if Knwn

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

O I P E
JUN 10 2002

O I P E
JUN 10 2002

PATENT & TRADEMARK OFFICE

JUN 12 2002

TECH CENTER 1600/2800

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Derwent Abstract 95-382760/49, "Fused bicyclics as gonadotropin releasing hormone antagonists - used for treating hormone related cancers, benign prostatic hypertrophy, acne vulgaris, etc. (Eng)"	
		Derwent Abstract 93-299636/38, "New condensed heterocyclic oligo-glutamate derivs. - used as water soluble antitumour agent and have good storage stability in cells"	1600/2800
		Derwent Abstract 93-078155/10, "New antitumour condensed pyrimidine derivs. - for treating chorlocarcinoma, leukaemia, breast adenocarcinoma, squamous cell carcinoma, lung cancer, lympho sarcoma, etc. and also rheumatism (Eng)"	
		Derwent Abstract 92-218561/27, "Antitumoural condensed heterocyclic oligo:glutamate derivs. - for treating leukaemia, squamous cell carcinoma, lymphatic sarcoma, small cell cancer of the lung etc. (Eng)"	
		Derwent Abstract 96-267825/27, "New hexa:hydro benz(e)isoindole cpds. - are useful in treatment of benign prostatic hyperplasia (Eng)"	
		Derwent Abstract 94-248420/30, "Furano- and thieno- (3,2-c)piperidone carboxamido-acids - are fibrinogen receptor antagonists, inhibit blood platelet aggregation, used in thrombi and emboli treatment:	
		Derwent Abstract 91-075241/11, "Heterocyclic peptide derivs. useful as renin inhibitors - in the treatment of hypertension, congestive heart failure, retro-viral diseases and central nervous system disorders"	
		HCA PLUS Abstract 1996:580284: "Preparation of heterocycl-substituted benz[3]isoindoles as x1 adrenergic antagonists"	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.